Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lumateperone - Intra-Cellular Therapies

Drug Profile

Lumateperone - Intra-Cellular Therapies

Alternative Names: CAPLYTA; ITI-007; ITI-722; Lumateperone tosylate

Latest Information Update: 10 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Intra-Cellular Therapies
  • Class Antidementias; Antidepressants; Antipsychotics; Behavioural disorder therapies; Fluorobenzenes; Piperidines; Pyrroles; Quinoxalines; Sleep disorder therapies; Small molecules; Tosyl compounds
  • Mechanism of Action Dopamine D2 receptor modulators; Glutamate modulators; Serotonin 2A receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar depression; Schizophrenia
  • Phase III Behavioural disorders; Major depressive disorder
  • Phase II Sleep maintenance insomnia

Most Recent Events

  • 04 May 2023 The US approved label for lumateperone includes a black boxed warning of an increased risk of death in elderly patients with dementia-related psychosis. CAPLYTA is not approved for use in pediatric patients
  • 04 May 2023 Intra-Cellular Therapies initiates a phase III 'Study-505' trial for Major depressive disorders (In adults, In the elderly, Adjunctive therapy) in USA (NCT05850689)
  • 06 Apr 2023 Intra-Cellular Therapies plans a phase III 'Study-505' trial for Major depressive disorders (Adjunctive therapy) in 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top